SG10201914022QA - Checkpoint blockade and microsatellite instability - Google Patents

Checkpoint blockade and microsatellite instability

Info

Publication number
SG10201914022QA
SG10201914022QA SG10201914022QA SG10201914022QA SG10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA SG 10201914022Q A SG10201914022Q A SG 10201914022QA
Authority
SG
Singapore
Prior art keywords
microsatellite instability
checkpoint blockade
checkpoint
blockade
microsatellite
Prior art date
Application number
SG10201914022QA
Inventor
Diaz Luis
Vogelstein Bert
W Kinzler Kenneth
Papadopoulos Nickolas
Le Dung
L Topalian Suzanne
M Pardoll Drew
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55955037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914022Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG10201914022QA publication Critical patent/SG10201914022QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201914022QA 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability SG10201914022QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079357P 2014-11-13 2014-11-13
US201562190977P 2015-07-10 2015-07-10

Publications (1)

Publication Number Publication Date
SG10201914022QA true SG10201914022QA (en) 2020-03-30

Family

ID=55955037

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201914022QA SG10201914022QA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability
SG11201703541PA SG11201703541PA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201703541PA SG11201703541PA (en) 2014-11-13 2015-11-12 Checkpoint blockade and microsatellite instability

Country Status (9)

Country Link
US (14) US20170313775A1 (en)
EP (3) EP3218004A4 (en)
JP (4) JP2017537087A (en)
KR (5) KR20170080697A (en)
CN (2) CN106999582A (en)
AU (3) AU2015346295A1 (en)
CA (1) CA2966660A1 (en)
SG (2) SG10201914022QA (en)
WO (1) WO2016077553A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3081576T (en) 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
SG10201914022QA (en) 2014-11-13 2020-03-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
MA40737A (en) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
CN113603784A (en) 2015-05-29 2021-11-05 艾吉纳斯公司 anti-CTLA-4 antibodies and methods of use thereof
MX2018002315A (en) 2015-09-01 2018-04-11 Agenus Inc Anti-pd-1 antibodies and methods of use thereof.
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
MX2018010361A (en) * 2016-02-29 2019-07-08 Genentech Inc Therapeutic and diagnostic methods for cancer.
CN109476731A (en) 2016-02-29 2019-03-15 基础医药有限公司 The method for the treatment of cancer
JP7267012B2 (en) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド Anti-TIM-3 antibody and method of use thereof
KR102515509B1 (en) * 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 Use of Anti-PD-1 Antibodies in the Treatment of Patients with Colorectal Cancer
MX2019002968A (en) * 2016-09-21 2019-10-15 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer.
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
MX2019003683A (en) 2016-10-11 2019-08-22 Agenus Inc Anti-lag-3 antibodies and methods of use thereof.
JP7106538B2 (en) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド Antibodies and methods of their use
MD3551660T2 (en) 2016-12-07 2024-03-31 Agenus Inc Anti-CTLA-4 antibodies and methods of use thereof
CN106834479A (en) * 2017-02-16 2017-06-13 凯杰（苏州）转化医学研究有限公司 Microsatellite instability state analysis system in immunotherapy of tumors
KR20190133213A (en) * 2017-03-31 2019-12-02 브리스톨-마이어스 스큅 컴퍼니 How to treat a tumor
PT3630112T (en) 2017-06-02 2024-04-23 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
US11104938B2 (en) 2017-06-20 2021-08-31 Bio-Rad Laboratories, Inc. Digital amplification assays for genetic instability
AU2018304458B2 (en) * 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
US20200239577A1 (en) * 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
CA3079253A1 (en) 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
WO2019108807A1 (en) * 2017-12-01 2019-06-06 Personal Genome Diagnositics Inc. Process for microsatellite instability detection
CN108220405A (en) * 2018-02-06 2018-06-29 上海汇真生物科技有限公司 The method and kit of microsatellite stability state-detection
MA52789A (en) 2018-02-13 2021-04-14 Merck Sharp & Dohme CANCER TREATMENT METHODS WITH ANTI-PD-1 ANTIBODIES
SG11202100344WA (en) 2018-07-23 2021-02-25 Guardant Health Inc Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
US20210292851A1 (en) * 2018-07-27 2021-09-23 Roche Sequencing Solutions, Inc. Method of monitoring effectiveness of immunotherapy of cancer patients
CA3109539A1 (en) 2018-08-31 2020-03-05 Guardant Health, Inc. Microsatellite instability detection in cell-free dna
US20200118644A1 (en) * 2018-10-15 2020-04-16 Tempus Labs, Inc. Microsatellite instability determination system and related methods
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
JP2022513068A (en) * 2018-11-15 2022-02-07 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド How to Improve Prediction of Responses in Cancer Patients Treated with Immunotherapy
EP3997625A4 (en) * 2019-10-29 2022-11-09 Samsung Electronics Co., Ltd. Electronic apparatus and method for controlling thereof
WO2021127267A1 (en) * 2019-12-18 2021-06-24 The Board Of Trustees Of The Leland Stanford Junior University Method for determining if a tumor has a mutation in a microsatellite
WO2021146266A1 (en) 2020-01-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer immunotherapy
CA3200667A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA43460A (en) 1893-07-03 Robert Wellington Bigger Furnace
CA62924A (en) 1898-12-27 1899-03-25 Azarie Mireault Medicinal compound
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
CA2592504A1 (en) * 2003-12-27 2005-07-14 Aros Applied Biotechnology Aps Classification of cancer
CN101213297B (en) 2005-05-09 2013-02-13 小野药品工业株式会社 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
MX349463B (en) 2008-09-26 2017-07-31 Univ Emory Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
WO2010127782A1 (en) * 2009-05-04 2010-11-11 Roche Diagnostics Gmbh Use of dppiv/seprase as a marker for cancer
CN102230004B (en) * 2011-06-08 2012-12-26 北京阅微基因技术有限公司 Tumor cell microsatellite instable state complex amplification system and detection kit
BR122022015975B1 (en) * 2012-05-15 2024-01-02 Bristol-Myers Squibb Company MONOCLONAL ANTIBODIES, KIT FOR THE TREATMENT OF AN INDIVIDUAL AFFLICTED WITH A CANCER, PROCESS FOR MEASURING MEMBRANOUS PD-L1 ON ISOLATED TUMOR CELLS AND USE OF THE ANTIBODY OR A PORTION THAT BIDS TO THE ANTIGEN THEREOF
KR20150023811A (en) * 2012-06-21 2015-03-05 컴퓨젠 엘티디. Lsr antibodies, and uses thereof for treatment of cancer
SG10201805674YA (en) 2014-01-02 2018-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
SG10201914022QA (en) * 2014-11-13 2020-03-30 Univ Johns Hopkins Checkpoint blockade and microsatellite instability
KR102515509B1 (en) 2016-06-03 2023-03-28 브리스톨-마이어스 스큅 컴퍼니 Use of Anti-PD-1 Antibodies in the Treatment of Patients with Colorectal Cancer
CA2935432A1 (en) 2016-07-07 2018-01-07 Georgios Gerardos Immunoassay detection device

Also Published As

Publication number Publication date
WO2016077553A1 (en) 2016-05-19
AU2019201671A1 (en) 2019-04-04
US11753468B2 (en) 2023-09-12
US11325975B2 (en) 2022-05-10
US11629187B2 (en) 2023-04-18
KR20170080697A (en) 2017-07-10
EP4098278A1 (en) 2022-12-07
US20220275086A1 (en) 2022-09-01
KR20220054710A (en) 2022-05-03
US20190023787A1 (en) 2019-01-24
US11339219B2 (en) 2022-05-24
US20210324077A1 (en) 2021-10-21
JP2019142881A (en) 2019-08-29
EP3218004A4 (en) 2018-06-13
US20210155693A1 (en) 2021-05-27
KR20210069124A (en) 2021-06-10
US20230365677A1 (en) 2023-11-16
US10934356B2 (en) 2021-03-02
US11634491B2 (en) 2023-04-25
US11649287B2 (en) 2023-05-16
US20210324078A1 (en) 2021-10-21
US11718668B2 (en) 2023-08-08
CN106999582A (en) 2017-08-01
EP3218004A1 (en) 2017-09-20
US20220259312A1 (en) 2022-08-18
JP2021095410A (en) 2021-06-24
US20220056129A1 (en) 2022-02-24
CN113694193A (en) 2021-11-26
US20210107978A1 (en) 2021-04-15
KR20230030022A (en) 2023-03-03
AU2021202086A1 (en) 2021-04-29
US20170267760A1 (en) 2017-09-21
KR20190135563A (en) 2019-12-06
US20210395365A1 (en) 2021-12-23
US11643462B2 (en) 2023-05-09
US20230026716A1 (en) 2023-01-26
US11325974B2 (en) 2022-05-10
CA2966660A1 (en) 2016-05-19
SG11201703541PA (en) 2017-05-30
AU2015346295A1 (en) 2017-05-25
US20170313775A1 (en) 2017-11-02
JP2023053140A (en) 2023-04-12
US20210130463A1 (en) 2021-05-06
EP3888679A1 (en) 2021-10-06
JP2017537087A (en) 2017-12-14
US11591393B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
SG10201914022QA (en) Checkpoint blockade and microsatellite instability
IL280791A (en) Deuterated compounds and uses thereof
ZA201608889B (en) Residence structures and related methods
HK1243073A1 (en) Therapeutic compounds and uses thereof
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
LT3215147T (en) Neuro-attenuating norketamine compounds and methods
GB201516882D0 (en) Methods and systems for updating user profiles
GB201413355D0 (en) Compositons and methods
HUE044571T2 (en) Modified cyclopentapeptides and uses thereof
GB201404470D0 (en) Therapeutic methods and materials
SG11201704498QA (en) Computing systems and methods
SG11201704473WA (en) New methods and uses
HK1243342A1 (en) Compounds and methods
IL247325A0 (en) Therapeutic methods employing noribogaine and related compounds
EP3214323A4 (en) Fastening structure and fastening method
GB201517786D0 (en) Methods and materials
GB201408091D0 (en) Methods and uses
PL3145465T3 (en) Closure assemblies using extended fingerlifts
GB2530711B (en) Security composition and use thereof
PL3229772T3 (en) 6-aryl-9-glycosylpurines and use thereof
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses
GB201407596D0 (en) New compounds and uses
GB201407599D0 (en) New compounds and uses